Tadaaki Yamada
Reproducibility track record
1
assessed papers
85/100
mean reproducibility
1
reproduced (C1–C2)
0
flagged
52
total citations
flag rate:
0%
(0/1)
The share of this author’s assessed papers carrying a ⚑ flag. A concentration is a prompt for expert review — never, on its own, a determination about the person.
Authorship role
first author: 0
last author: 0
Topics
Funders
—
Frequent co-authors
Ayano Ueno 1Ko Umetsu 1Masaru Tomita 1Seiji Yano 1Takeharu Sakamoto 1Yasuhiko Nishioka 1Sho Tabata 1Fumie Nakasuka 1Tomoyoshi Soga 1Akiyoshi Hirayama 1
Institutions
Keio University 1Systems Biology Institute 1Keio University Shonan Fujisawa 1The University of Tokyo 1Yamagata University 1Protein Research Foundation 1
Geography (author institutions)
JP 1US 1
Co-author network
Collaborators, sized by shared output and coloured by their own reproducibility (green = high, red = low). Click a node to open their card. A pattern is a prompt for review, never a determination.
How this author’s assessed papers reproduced — the outcome of reproduction attempts, not a judgement of the person. Coverage is partial and grows over time.
Assessed papers (1)
Complete publication record (567)
Request a reproduction →1 assessed by us (1 reproduced) · 566 not yet assessed — every PubMed paper on record, linked below.
-
Abstract 1889: Elucidation and therapeutic strategies to overcome intrinsic resistance mechanisms in KRAS G12D-mutant tumors. ↗Cancer Research · 2026not yet assessed
-
Abstract 7292: Hypoxia-driven HIF-1α/YAP-AXL signaling drives adaptive resistance to TKIs in NSCLC ↗Cancer Research · 2026not yet assessed
-
Identification of Hidden Cachexia Subgroup in PD‐L1‐High NSCLC: Comparative Analysis of the AWGC vs. Fearon Criteria ↗Journal of Cachexia Sarcopenia and Muscle · 2026 · PMID 41967103not yet assessed
-
Predictive value of TTF-1 expression for stratifying outcomes between dual ICI and chemoimmunotherapy in patients with PD-L1-negative NSCLC ↗International Journal of Clinical Oncology · 2026not yet assessed
-
Gut microbiome-driven modulation of the tumor immune microenvironment optimizes dual checkpoint blockade in advanced non-small-cell lung cancer ↗ESMO Open · 2026 · PMID 41702355not yet assessed
-
Phase II study of ramucirumab plus erlotinib for treatment-naïve patients with EGFR-mutant non-squamous non-small cell lung cancer and pleural effusion (RELAY-Effusion) ↗Lung Cancer · 2026 · PMID 42096800not yet assessed
-
Initial biomarker testing strategies and clinical outcomes in advanced non-small cell lung cancer ↗iScience · 2026 · PMID 42205705not yet assessed
-
Efficacy and safety of nintedanib for older adults with idiopathic pulmonary fibrosis or progressive fibrosing interstitial lung disease: A multicenter retrospective study in Japan ↗Respiratory Investigation · 2026 · PMID 42247823not yet assessed
-
Exploration of clinical Biomarkers for guiding treatment selection between chemotherapy and combination therapy with Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel in EGFR-Mutant NSCLC patients after EGFR-TKI Therapy: The SPIRAL-STEP study ↗Lung Cancer · 2025 · PMID 39970730not yet assessed
-
Utility of serum CYFRA 21-1 as a prognostic biomarker in ALK-positive non-small cell lung cancer treated with ALK-TKIs: a retrospective cohort study ↗Translational Lung Cancer Research · 2025 · PMID 40673106not yet assessed
-
Impact of EGFR Mutation Subtypes on Response to Chemoimmunotherapy and Chemotherapy in Non-Small-Cell Lung Cancer After EGFR-TKI Failure ↗Targeted Oncology · 2025 · PMID 40274716not yet assessed
-
Atezolizumab with carboplatin plus nab-paclitaxel combination therapy for TTF-1 negative advanced nonsquamous non–small cell lung cancer: A multicenter, single-arm phase 2 trial (F1NE TUNE, LOGiK 2102) ↗European Journal of Cancer · 2025 · PMID 40961811not yet assessed
-
Regimen Selection for Chemoimmunotherapy in Nonsquamous Non–Small Cell Lung Cancer with Low PD-L1 Expression: A Multicenter Retrospective Cohort Study ↗Clinical Lung Cancer · 2025 · PMID 39864962not yet assessed
-
Prevalence and molecular landscape of NRG1 fusions in Japanese solid tumors: a nationwide data analysis using the C-CAT database ↗Lung Cancer · 2025 · PMID 41242285not yet assessed
-
Impact of immune-related adverse events on clinical outcomes in patients with advanced non-small cell lung cancer with low PD-L1 expression, focusing on pneumonitis: a multicenter retrospective study in Japan ↗Translational Lung Cancer Research · 2025 · PMID 40386739not yet assessed
-
Chemoimmunotherapy Outcomes and Prognostic Factors in Patients with Advanced, Low PD-L1–Expressing Non–Small Cell Lung Cancer ↗Cancer Research Communications · 2025 · PMID 40637162not yet assessed
-
Prolonged progression-free survival on epidermal growth factor receptor-tyrosine kinase inhibitors predicts superior response to atezolizumab-based therapy over chemotherapy in epidermal growth factor receptor-mutated non-small-cell lung cancer following progression ↗ESMO Real World Data and Digital Oncology · 2025 · PMID 41647697not yet assessed
-
Real-world treatment outcomes before and after chemoimmunotherapy approval in EGFR-mutant NSCLC after EGFR-TKI failure: a Japanese cohort study ↗International Journal of Clinical Oncology · 2025 · PMID 40691734not yet assessed
-
Immune checkpoint inhibitor-induced interstitial lung disease with and without CTLA-4 regimen in non-small cell lung cancer patients and PD-L1 < 1 %: A multicenter, retrospective study ↗Lung Cancer · 2025 · PMID 41046781not yet assessed
-
Study protocol of an open-label prospective phase II study of Durvalumab plus Carboplatin and Etoposide in advanced large cell neuroendocrine carcinoma of the lung (LOGIK2401: NECTAR study) ↗Cancer Treatment and Research Communications · 2025 · PMID 41037966not yet assessed
-
Outcomes of chemotherapy with or without immunotherapy in older patients with non-small cell lung cancer and low PD-L1 expression ↗Translational Lung Cancer Research · 2025 · PMID 40535088not yet assessed
-
Durvalumab, carboplatin, and etoposide in patients who are treatment-naive with extensive-stage small-cell lung cancer and poor performance status (NEJ045A): a single-arm phase 2 trial ↗The Lancet Respiratory Medicine · 2025 · PMID 41033335not yet assessed
-
MA02.06 Efficacy and Safety of 1L Olomorasib Plus Pembrolizumab in KRAS G12C-Mutant NSCLC: Results From LOXO-RAS-20001 and SUNRAY-01 ↗Journal of Thoracic Oncology · 2025not yet assessed
-
Updated analysis from NEJ045A study: Safety and efficacy of durvalumab plus carboplatin and etoposide for previously untreated extensive-stage small-cell lung cancer patients with a poor performance status. ↗Journal of Clinical Oncology · 2025not yet assessed
-
Comparative analysis of first-line treatment in NSCLC including unresectable stage III (IIIB/IIIC) and stage IV with low PD-L1 expression: Clinical trial eligible versus ineligible patients ↗Lung Cancer · 2025 · PMID 39889466not yet assessed
-
AXL-SHC1 Signaling Axis Mediates Intrinsic Resistance to HER2-Targeted Tyrosine Kinase Inhibitors in HER2-Aberrant Lung and Gastric Cancers ↗SSRN Electronic Journal · 2025not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
Abstract 1721: AXL signaling promotes adaptive resistance to HER2 tyrosine kinase inhibitors in HER2 aberrant tumor cells ↗Cancer Research · 2025not yet assessed
-
Abstract 5532: Combinational targeted therapy effects on EphA2 and KRAS G12C inhibitor against KRAS G12C mutated non-small cell lung cancer cells ↗Cancer Research · 2025not yet assessed
-
Abstract 5617: Development of an initial triple combination therapy targeting EGFR, AXL, and FGFR for EGFR-mutated non-small cell lung cancer ↗Cancer Research · 2025not yet assessed
-
Abstract 4720: Evaluation of lorlatinib efficacy using plasma DNA ↗Cancer Research · 2025not yet assessed
-
Evaluating the Impact of Renal Function Assessment Methods on Pemetrexed-Based Chemoimmunotherapy in Patients with Non-Small Cell Lung Cancer and Low Programmed Death-Ligand 1 Expression ↗SSRN Electronic Journal · 2025not yet assessed
-
Impact of mutant protein expression on clinical outcomes in patients with EGFR L858R-mutated non-small cell lung cancer ↗Translational Lung Cancer Research · 2025 · PMID 40673090not yet assessed
-
Atezolizumab with Carboplatin Plus Nab-Paclitaxel Combination Therapy for TTF-1 Negative Advanced Nonsquamous Non–Small Cell Lung Cancer: A Multicenter, Single-Arm Phase 2 Trial (F1NE TUNE, LOGiK 2102) ↗SSRN Electronic Journal · 2025not yet assessed
-
Analysis of Poor Prognostic Factors and Treatment Strategies in Platinum-Based Systemic Therapy After EGFR-TKI Failure in Patients With Advanced Nonsmall Cell Lung Cancer Harboring EGFR Mutations ↗Clinical Lung Cancer · 2025 · PMID 40816949not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
P1.11.11 Survival Impact of Pneumonitis in Older Patients With Non-Squamous NSCLC Treated With Pembrolizumab and Pemetrexed: Insights From CJLSG1901 ↗Journal of Thoracic Oncology · 2025not yet assessed
-
Efficacy and Safety of Chemoimmunotherapy in Patients With Advanced Non-small Cell Lung Cancer With Pre-existing Interstitial Pneumonia and Low PD-L1 Expression ↗Anticancer Research · 2025 · PMID 41151889not yet assessed
-
Hydrostatic pressure from basal side promotes cancer proliferation, enhances migration, and alters cell polarity: A model of the effects of interstitial fluid pressure in tumor microenvironment ↗Molecular Biology of the Cell · 2025 · PMID 41259157not yet assessed
-
not yet assessed
-
Selecting optimal immunotherapy based on inflammation in stage IV PD-L1 ≥50% gene mutation-negative non-small cell lung cancer: pembrolizumab monotherapy versus combination chemoimmunotherapy ↗Translational Lung Cancer Research · 2025 · PMID 41367575not yet assessed
-
Triple combination therapy comprising osimertinib, an AXL inhibitor, and an FGFR inhibitor improves the efficacy of EGFR-mutated non-small cell lung cancer ↗Cancer Letters · 2024 · PMID 39059573not yet assessed
-
AXL signal mediates adaptive resistance to KRAS G12C inhibitors in KRAS G12C-mutant tumor cells ↗Cancer Letters · 2024 · PMID 38342232not yet assessed
-
Nationwide data from comprehensive genomic profiling assays for detecting driver oncogenes in non‐small cell lung cancer ↗Cancer Science · 2024 · PMID 38450844not yet assessed
-
Epithelial-mesenchymal transition status is a remarkable biomarker for the combination treatment with avutometinib and defactinib in KRAS-mutated non-small cell lung cancer ↗British Journal of Cancer · 2024 · PMID 38822146not yet assessed
-
CYFRA 21-1 predicts efficacy of combined chemoimmunotherapy in patients with advanced non-small cell lung cancer: a prospective observational study ↗Translational Lung Cancer Research · 2024 · PMID 39263030not yet assessed
-
Clinical impact of cancer cachexia on the outcome of patients with non-small cell lung cancer with PD-L1 tumor proportion scores of ≥50% receiving pembrolizumab monotherapy versus immune checkpoint inhibitor with chemotherapy ↗OncoImmunology · 2024 · PMID 39681395not yet assessed
-
Impact of TTF-1 Expression on the Prognostic Prediction of Patients with Non–Small Cell Lung Cancer with PD-L1 Expression Levels of 1% to 49%, Treated with Chemotherapy vs. Chemoimmunotherapy: A Multicenter, Retrospective Study ↗Cancer Research and Treatment · 2024 · PMID 39482992not yet assessed
-
YAP Regulates HER3 Signaling–Driven Adaptive Resistance to RET Inhibitors in RET-Aberrant Cancers ↗Clinical Cancer Research · 2024 · PMID 39495173not yet assessed
-
Unraveling the influence of TTF-1 expression on immunotherapy outcomes in PD-L1-high non-squamous NSCLC: a retrospective multicenter study ↗Frontiers in Immunology · 2024 · PMID 39076994not yet assessed
-
Prospective Observational Study of Ramucirumab Plus Docetaxel After Combined Chemoimmunotherapy in Patients With Non-Small-Cell Lung Cancer ↗The Oncologist · 2024 · PMID 38241181not yet assessed
-
Depth of response and treatment outcomes of immune checkpoint inhibitor-based therapy in patients with advanced non-small cell lung cancer and high PD-L1 expression: An exploratory analysis of retrospective multicenter cohort ↗Investigational New Drugs · 2024 · PMID 39168900not yet assessed
-
Clinical significance of chronic pulmonary aspergillosis in lung cancer patients undergoing anticancer drug therapy ↗Thoracic Cancer · 2024 · PMID 39090758not yet assessed
-
Initial AXL and MCL‐1 inhibition contributes to abolishing lazertinib tolerance in EGFR‐mutant lung cancer cells ↗Cancer Science · 2024 · PMID 39039802not yet assessed
-
Prognostic impact of clinical factors for immune checkpoint inhibitor with or without chemotherapy in older patients with non-small cell lung cancer and PD-L1 TPS ≥ 50% ↗Frontiers in Immunology · 2024 · PMID 38464519not yet assessed
-
Efficacy and Safety of Docetaxel plus Ramucirumab for Patients with Pretreated Advanced or Recurrent Non-small Cell Lung Cancer: Focus on Older Patients ↗Targeted Oncology · 2024 · PMID 38467958not yet assessed
-
The Significance of Longitudinal Psoas Muscle Loss in Predicting the Maintenance Efficacy of Durvalumab Treatment Following Concurrent Chemoradiotherapy in Patients with Non-Small Cell Lung Cancer: A Retrospective Study ↗Cancers · 2024 · PMID 39272894not yet assessed
-
EGFR-V834L combined with L858R mutation reduced afatinib sensitivity and associated to early recurrence in lung cancer ↗Translational Lung Cancer Research · 2024 · PMID 39670006not yet assessed
-
POLD1 Is Required for Cell Cycle Progression by Overcoming DNA Damage in Malignant Pleural Mesothelioma ↗Cancer Genomics & Proteomics · 2024 · PMID 38423601not yet assessed
-
Results of a Survey on Early Careers Among Members of the Japan Lung Cancer Society in Fiscal Year 2023 ↗Haigan · 2024not yet assessed
-
Patients’ Trajectory With Lung Cancer From Treatment Initiation to End-Of-Life: A Retrospective Cohort Study Using Claims Data in Japan ↗Cancer Control · 2024 · PMID 39613477not yet assessed
-
Pembrolizumab and Pemetrexed for Older Patients With Nonsquamous NSCLC and Programmed Cell Death-Ligand 1 Tumor Proportion Scores of Less Than 50% ↗JTO Clinical and Research Reports · 2024 · PMID 40007549not yet assessed
-
Safety and efficacy of durvalumab plus carboplatin and etoposide for patients with previously untreated extensive-stage small-cell lung cancer (ES-SCLC) with a poor performance status: The results from phase II single-arm study (NEJ045A study). ↗Journal of Clinical Oncology · 2024not yet assessed
-
Phase 2 study of pembrolizumab plus pemetrexed for older patients with non-squamous non-small cell lung cancer with PD-L1 tumor proportion score of less than 50%: CJLSG1901. ↗Journal of Clinical Oncology · 2024not yet assessed
-
Impact of the response to platinum-based chemotherapy on the second-line immune checkpoint inhibitor monotherapy in non-small cell lung cancer with PD-L1 expression ≤49%: a multicenter retrospective study ↗Frontiers in Oncology · 2024 · PMID 38344209not yet assessed
-
Comparing Three Different Anti–Programmed Death-Ligand 1 Antibodies in Immunohistochemical Evaluation of Combined Chemoimmunotherapy Response in Patients With NSCLC: A Prospective Study ↗JTO Clinical and Research Reports · 2024 · PMID 38444594not yet assessed
-
not yet assessed
-
not yet assessed
-
Data from Effects of Combined Therapeutic Targeting of AXL and ATR on Pleural Mesothelioma Cells ↗2024not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
Data from Effects of Combined Therapeutic Targeting of AXL and ATR on Pleural Mesothelioma Cells ↗2024not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
Abstract 7194: Targeting AXL and MCL-1 to eradicate lazertinib tolerance in EGFR-mutated NSCLC cells ↗Cancer Research · 2024not yet assessed
-
Abstract 3730: Impact of proton pump inhibitor on ICI with or without chemotherapy for NSCLC with high PD-L1 TPS ↗Cancer Research · 2024not yet assessed
-
not yet assessed
-
Abstract 1941: AXL activation promotes adaptive resistance to KRAS-G12C inhibitors in KRAS-G12C-mutated non-small cell lung cancer ↗Cancer Research · 2024not yet assessed
-
1341P Exploring the role of the gut microbiome on the efficacy of ipilimumab and nivolumab in advanced non-small cell lung cancer: A prospective observational study ↗Annals of Oncology · 2024not yet assessed
-
not yet assessed
-
Concomitant Proton Pump Inhibitor Use With Pembrolizumab Monotherapy vs Immune Checkpoint Inhibitor Plus Chemotherapy in Patients With Non−Small Cell Lung Cancer ↗JAMA Network Open · 2023 · PMID 37432682not yet assessed
-
A phase 2 trial of durvalumab treatment following radiation monotherapy in patients with non-small cell lung cancer ineligible for stage III chemoradiotherapy: The SPIRAL-RT study ↗European Journal of Cancer · 2023 · PMID 37890349not yet assessed
-
Adaptive resistance to lorlatinib via EGFR signaling in ALK-rearranged lung cancer ↗npj Precision Oncology · 2023 · PMID 36702855not yet assessed
-
The landscape of cancer cachexia in advanced non-small cell lung cancer: a narrative review ↗Translational Lung Cancer Research · 2023 · PMID 36762058not yet assessed
-
Age-Stratified Analysis of First-Line Chemoimmunotherapy for Extensive-Stage Small Cell Lung Cancer: Real-World Evidence from a Multicenter Retrospective Study ↗Cancers · 2023 · PMID 36900334not yet assessed
-
The landscape of immune therapy in vulnerable patients with advanced non-small cell lung cancer: a narrative review ↗Translational Lung Cancer Research · 2023 · PMID 38090528not yet assessed
-
TTF-1 Expression and Clinical Outcomes of Combined Chemoimmunotherapy in Patients With Advanced Lung Adenocarcinoma: A Prospective Observational Study ↗JTO Clinical and Research Reports · 2023 · PMID 37020925not yet assessed
-
Predictive value of p53 and AXL immunostaining for the efficacy of immune checkpoint inhibitor-based therapy after osimertinib treatment in patients with epidermal growth factor-mutant non-small cell lung cancer ↗Cancer Immunology Immunotherapy · 2023 · PMID 36617602not yet assessed
-
Prospective Observational Study Evaluating the Prognostic Value of the G8 Screening Tool for Extensive-Stage Small Cell Lung Cancer Patients Who Received Programmed Death-Ligand 1 Inhibitor plus Platinum–Etoposide Chemotherapy ↗Drugs & Aging · 2023 · PMID 37145245not yet assessed
-
Clinical Efficacy and Safety of First- or Second-Generation EGFR-TKIs after Osimertinib Resistance for EGFR Mutated Lung Cancer: A Prospective Exploratory Study ↗Targeted Oncology · 2023 · PMID 37610516not yet assessed
-
Predictive Value of Modified Glasgow Prognostic Score and Persistent Inflammation among Patients with Non-Small Cell Lung Cancer Treated with Durvalumab Consolidation after Chemoradiotherapy: A Multicenter Retrospective Study ↗Cancers · 2023 · PMID 37686634not yet assessed
-
Effects of Combined Therapeutic Targeting of AXL and ATR on Pleural Mesothelioma Cells ↗Molecular Cancer Therapeutics · 2023 · PMID 37802502not yet assessed
-
Analysis of Tumor Heterogeneity Through AXL Activation in Primary Resistance to EGFR Tyrosine Kinase Inhibitors ↗JTO Clinical and Research Reports · 2023 · PMID 37426308not yet assessed
-
Use of Phosphatidylcholine for Correction of Festoons ↗Dermatologic Surgery · 2023 · PMID 37184452not yet assessed
-
Comparison of the prognosis of symptomatic cerebral infarction and pulmonary embolism in patients with advanced non‐small cell lung cancer ↗Cancer Medicine · 2023 · PMID 36707978not yet assessed
-
Prophylactic treatment of dacomitinib‐induced skin toxicities in epidermal growth factor receptor‐mutated non–small‐cell lung cancer: A multicenter, Phase <scp>II</scp> trial ↗Cancer Medicine · 2023 · PMID 37269194not yet assessed
-
Exploratory analysis of immunochemotherapy compared to chemotherapy after <scp>EGFR‐TKI</scp> in non–small cell lung cancer patients with <scp>EGFR</scp> mutation: A multicenter retrospective study ↗Thoracic Cancer · 2023 · PMID 36866788not yet assessed
-
Early Tumor Shrinkage as a Predictor of Favorable Treatment Outcomes in Patients With Extensive-Stage SCLC Who Received Programmed Cell Death-Ligand 1 Inhibitor Plus Platinum-Etoposide Chemotherapy: A Prospective Observational Study ↗JTO Clinical and Research Reports · 2023 · PMID 37025120not yet assessed
-
Etoposide soft capsule combined with anlotinib in the third-line treatment of advanced non-small cell lung cancer: a retrospective cohort study ↗Journal of Thoracic Disease · 2023 · PMID 37969289not yet assessed
-
Significance of localized expression of full-length growth differentiation factor-15 in cachexia of advanced non-small cell lung cancer ↗Supportive Care in Cancer · 2023 · PMID 37115357not yet assessed
-
Recurrence of Large-Vessel Vasculitis Induced by Multiple Types of Granulocyte Colony-Stimulating Factor Preparation in Patient with Large-Cell Neuroendocrine Lung Carcinoma: A Case Report ↗Case Reports in Oncology · 2023 · PMID 37900825not yet assessed
-
First-Line Chemoimmunotherapy versus Sequential Platinum-Based Chemotherapy Followed by Immunotherapy in Patients with Non-Small Cell Lung Cancer with ≤49% Programmed Death-Ligand 1 Expression: A Real-World Multicenter Retrospective Study ↗Cancers · 2023 · PMID 37894357not yet assessed
-
Chemoimmunotherapy Versus Pembrolizumab as a First-Line Treatment for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression: Focus on the Role of Performance Status ↗Targeted Oncology · 2023 · PMID 37902896not yet assessed
-
Rationale and design of phase II clinical trial of dual inhibition with ramucirumab and erlotinib in <i>EGFR</i> exon 19 deletion-positive treatment-naïve non-small cell lung cancer with high PD-L1 expression (SPIRAL-3D study) ↗Therapeutic Advances in Medical Oncology · 2023 · PMID 37333903not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
Abstract 410: Tumor heterogeneity via AXL activation on primary resistance to EGFR tyrosine kinase inhibitors in EGFR mutated lung cancer ↗Cancer Research · 2023not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
Abstract 594: Effects of interstitial pressure on lung cancer cells ↗Cancer Research · 2023not yet assessed
-
Abstract 4015: EGFR activation via c-Jun axis promotes adaptive resistance to third generation ALK-TKI lorlatinib in ALK-rearranged non-small cell lung cancer cells ↗Cancer Research · 2023not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
A Case of Takotsubo Cardiomyopathy Triggered by Asthma Exacerbation After mRNA-based Vaccination for COVID-19 ↗Cureus · 2023 · PMID 37362462not yet assessed
-
Endobronchial metastasis of hepatocellular carcinoma treated with Lenvatinib: A case report ↗Respirology Case Reports · 2023 · PMID 37614813not yet assessed
-
1426P Real-world data on next-generation sequencing using comprehensive genomic profiling assays for detecting driver oncogenes in advanced non-small cell lung cancer: Analysis with the National Database of Japan ↗Annals of Oncology · 2023not yet assessed
-
not yet assessed
-
25P Role of AXL activation on adaptive resistance to KRAS-G12C inhibitors in KRAS-G12C-mutated non-small cell lung cancer ↗Annals of Oncology · 2023not yet assessed
-
P2.09-25 Inhibition of AXL and Mcl-1 Contributes to Eradicating Tolerance to EGFR-TKI Lazertinib in Lung Cancer Cells Expressing Mutant EGFR ↗Journal of Thoracic Oncology · 2023not yet assessed
-
P2.05-07 Roles of p53 and AXL Expressions on the Efficacy of ICI-Based Therapy in Patients with EGFR Mutated Lung Cancer after Osimertinib ↗Journal of Thoracic Oncology · 2023not yet assessed
-
P2.05-01 Clinical impact of TTF-1 for Combined Chemoimmunotherapy Efficacy in Lung Adenocarcinoma: A Multicenter Prospective Study ↗Journal of Thoracic Oncology · 2023not yet assessed
-
MO57-6 Comprehensive genomic profiling is effective in determining treatment decisions for advanced solid tumors patients ↗Annals of Oncology · 2023not yet assessed
-
MO38-3 EGFR activation elicited adaptive resistance to lorlatinib in ALK-rearranged non-small cell lung cancer cells ↗Annals of Oncology · 2023not yet assessed
-
Epithelial-mesenchymal transition status is a remarkable biomarker for the combination treatment with avutometinib and defactinib in KRAS-mutated non-small cell lung cancer ↗Research Square · 2023not yet assessed
-
529P Ramucirumab plus docetaxel after combination chemoimmunotherapy in patients with non-small cell lung cancer: A prospective observational study ↗Annals of Oncology · 2023not yet assessed
-
531P Effect of combinational targeted therapy for AXL and ATR against malignant mesothelioma cells ↗Annals of Oncology · 2023not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
Prognostic Nutritional Index and Lung Immune Prognostic Index as Prognostic Predictors for Combination Therapies of Immune Checkpoint Inhibitors and Cytotoxic Anticancer Chemotherapy for Patients with Advanced Non-Small Cell Lung Cancer ↗Diagnostics · 2022 · PMID 35204513not yet assessed
-
HER3 activation contributes toward the emergence of ALK inhibitor-tolerant cells in ALK-rearranged lung cancer with mesenchymal features ↗npj Precision Oncology · 2022 · PMID 35042943not yet assessed
-
Safety and Immunogenicity of mRNA Vaccines Against Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Lung Cancer Receiving Immune Checkpoint Inhibitors: A Multicenter Observational Study in Japan ↗Journal of Thoracic Oncology · 2022 · PMID 35752437not yet assessed
-
High levels of <scp>AXL</scp> expression in untreated <scp><i>EGFR</i></scp>‐mutated non‐small cell lung cancer negatively impacts the use of osimertinib ↗Cancer Science · 2022 · PMID 36169649not yet assessed
-
A multicenter-retrospective study of non-small-cell lung carcinoma harboring uncommon epidermal growth factor receptor (EGFR) mutations: different subtypes of EGFR exon 19 deletion-insertions exhibit the clinical characteristics and prognosis of non-small cell lung carcinoma ↗Translational Lung Cancer Research · 2022 · PMID 35280318not yet assessed
-
<scp>Pan‐HER</scp> inhibitors overcome lorlatinib resistance caused by <scp>NRG1</scp>/<scp>HER3</scp> activation in <scp><i>ALK</i></scp>‐rearranged lung cancer ↗Cancer Science · 2022 · PMID 36086904not yet assessed
-
Changes in serum transforming growth factor-beta concentration as a predictive factor for radiation-induced lung injury onset in radiotherapy-treated patients with locally advanced lung cancer ↗Translational Lung Cancer Research · 2022 · PMID 36248323not yet assessed
-
Pembrolizumab monotherapy for untreated PD-L1-Positive non-small cell lung cancer in the elderly or those with poor performance status: A prospective observational study ↗Frontiers in Oncology · 2022 · PMID 36158655not yet assessed
-
Heterogeneity among tumors with acquired resistance to EGFR tyrosine kinase inhibitors harboring <i>EGFR</i>‐T790M mutation in non‐small cell lung cancer cells ↗Cancer Medicine · 2022 · PMID 35029047not yet assessed
-
A Real-World Analysis of Immune Checkpoint Inhibitor-Based Therapy After Osimertinib Treatment in Patients With EGFR-Mutant NSCLC ↗JTO Clinical and Research Reports · 2022 · PMID 36082280not yet assessed
-
Efficacy and Safety of Programmed Death-Ligand 1 Inhibitor Plus Platinum-Etoposide Chemotherapy in Patients With Extensive-Stage SCLC: A Prospective Observational Study ↗JTO Clinical and Research Reports · 2022 · PMID 35789793not yet assessed
-
Clinical impact of amrubicin monotherapy in patients with relapsed small cell lung cancer: a multicenter retrospective study ↗Translational Lung Cancer Research · 2022 · PMID 36248326not yet assessed
-
A real-world study on the safety of the extended dosing schedule for nivolumab and pembrolizumab in patients with solid tumors ↗International Immunopharmacology · 2022 · PMID 35436741not yet assessed
-
Efficacy and Safety of Paclitaxel/nab-paclitaxel Chemotherapy for Patients With Relapsed Small Cell Lung Cancer ↗Anticancer Research · 2022 · PMID 36191970not yet assessed
-
Efficacy and safety of immuno-chemotherapy in patients with advanced non-small-cell lung cancer harboring oncogenic mutations: a multicenter retrospective study ↗Journal of Cancer Research and Clinical Oncology · 2022 · PMID 35737092not yet assessed
-
Adaptive Resistance to Lorlatinib via EGFR Signaling in ALK-rearranged Lung Cancer ↗Research Square · 2022not yet assessed
-
Concurrent hemoptysis and pulmonary embolism associated with lenvatinib therapy for unresectable thymic carcinoma: A case report ↗Current Problems in Cancer Case Reports · 2022not yet assessed
-
Efficacy of immunochemotherapy compared with platinum-based chemotherapy and immunotherapy after tyrosine kinase inhibitor failure in advanced non-small cell lung cancer patients with EGFR mutation ↗Research Square · 2022not yet assessed
-
Corrigendum to “A real-world study on the safety of the extended dosing schedule for nivolumab and pembrolizumab in patients with solid tumors” [Int. Immunopharmacol. 108 (2022) 108775] ↗International Immunopharmacology · 2022 · PMID 36096994not yet assessed
-
Localized expression and role of full-length growth differentiation factor 15 in non-small cell lung cancer ↗Research Square · 2022not yet assessed
-
Clinical impact of pembrolizumab combined with chemotherapy in elderly patients with advanced non-small-cell lung cancer ↗Lung Cancer · 2021 · PMID 34500218not yet assessed
-
TGF-β-dependent reprogramming of amino acid metabolism induces epithelial–mesenchymal transition in non-small cell lung cancersCommunications Biology · 2021 · PMID 34168290L1 85/100
-
Impact of cancer cachexia on the therapeutic outcome of combined chemoimmunotherapy in patients with non-small cell lung cancer: a retrospective study ↗OncoImmunology · 2021 · PMID 34290909not yet assessed
-
Immune-Related Adverse Events Are Associated With Clinical Benefit in Patients With Non-Small-Cell Lung Cancer Treated With Immunotherapy Plus Chemotherapy: A Retrospective Study ↗Frontiers in Oncology · 2021 · PMID 33833990not yet assessed
-
Impact of tumor programmed death ligand-1 expression on osimertinib efficacy in untreated EGFR-mutated advanced non-small cell lung cancer: a prospective observational study ↗Translational Lung Cancer Research · 2021 · PMID 34584858not yet assessed
-
Plasma membrane anchored nanosensor for quantifying endogenous production of H2O2 in living cells ↗Biosensors and Bioelectronics · 2021 · PMID 33607416not yet assessed
-
Inhibition of c-Jun N-terminal kinase signaling increased apoptosis and prevented the emergence of ALK-TKI-tolerant cells in ALK-rearranged non-small cell lung cancer ↗Cancer Letters · 2021 · PMID 34534615not yet assessed
-
Androgen replacement therapy for cancer‐related symptoms in male: result of prospective randomized trial (ARTFORM study) ↗Journal of Cachexia Sarcopenia and Muscle · 2021 · PMID 34029455not yet assessed
-
Late-onset Pleural and Pericardial Effusion as Immune-related Adverse Events after 94 Cycles of Nivolumab ↗Internal Medicine · 2021 · PMID 34092733not yet assessed
-
Prognostic Markers of Survival among Japanese Patients with Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Receiving First-Line Alectinib ↗Diagnostics · 2021 · PMID 34943412not yet assessed
-
The Impact of VEGF Inhibition on Clinical Outcomes in Patients With Advanced Non-Small Cell Lung Cancer Treated With Immunotherapy: A Retrospective Cohort Study ↗Frontiers in Oncology · 2021 · PMID 34123822not yet assessed
-
Impact of docetaxel plus ramucirumab in a second‐line setting after chemoimmunotherapy in patients with non‐small‐cell lung cancer: A retrospective study ↗Thoracic Cancer · 2021 · PMID 34791812not yet assessed
-
Early discontinuation of induction therapy in chemoimmunotherapy as an effective alternative to the standard regimen in patients with non-small cell lung cancer: a retrospective study ↗Journal of Cancer Research and Clinical Oncology · 2021 · PMID 34510271not yet assessed
-
Prognostic factors in older patients with wild-type epidermal growth factor receptor advanced non-small cell lung cancer: a multicenter retrospective study ↗Translational Lung Cancer Research · 2021 · PMID 33569304not yet assessed
-
Naldemedine is effective in the treatment of opioid-induced constipation in patients with chronic non-cancer pain who had a poor response to laxatives ↗Therapeutic Advances in Gastroenterology · 2021 · PMID 34377150not yet assessed
-
Impact of maintenance therapy following induction immunochemotherapy for untreated advanced non-small cell lung cancer patients ↗Journal of Cancer Research and Clinical Oncology · 2021 · PMID 34825950not yet assessed
-
SY13-3 Novel therapeutic strategies for drug-tolerance in NSCLC with driver oncogenes ↗Annals of Oncology · 2021not yet assessed
-
MO2-5 Impact of pre-treatment AXL expression on EGFR-TKI efficacy in EGFR-mutated non-small cell lung cancer patients ↗Annals of Oncology · 2021not yet assessed
-
Impact of Maintenance Therapy Following Induction Immunochemotherapy for Untreated Advanced Non-Small Cell Lung Cancer Patients ↗Research Square · 2021not yet assessed
-
Immune Checkpoint Inhibitors for Lung Cancer Treatment: A Review ↗Journal of Clinical Medicine · 2020 · PMID 32384677not yet assessed
-
ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in <i>EGFR</i> -Mutated Non–Small Cell Lung Cancer ↗Clinical Cancer Research · 2020 · PMID 31953310not yet assessed
-
Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer ↗Nature Communications · 2020 · PMID 32929081not yet assessed
-
Significance of inflammatory indexes in atezolizumab monotherapy outcomes in previously treated non-small-cell lung cancer patients ↗Scientific Reports · 2020 · PMID 33060826not yet assessed
-
Endocrinopathies Associated with Immune Checkpoint Inhibitor Cancer Treatment: A Review ↗Journal of Clinical Medicine · 2020 · PMID 32610470not yet assessed
-
Association of immune checkpoint inhibitors with respiratory infections: A review ↗Cancer Treatment Reviews · 2020 · PMID 33038863not yet assessed
-
Safety and Efficacy of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Chronic Non-Cancer Pain Receiving Opioid Therapy: A Subgroup Analysis of Patients ≥ 65 Years of Age ↗Drugs & Aging · 2020 · PMID 32086791not yet assessed
-
Impact of preexisting antinuclear antibodies on combined immunotherapy and chemotherapy in advanced non-small cell lung cancer patients ↗Medical Oncology · 2020 · PMID 33175248not yet assessed
-
Final Results from a Phase II Trial of Osimertinib for Elderly Patients with Epidermal Growth Factor Receptor t790m-Positive Non-Small Cell Lung Cancer That Progressed during Previous Treatment ↗Journal of Clinical Medicine · 2020 · PMID 32517152not yet assessed
-
Rationale and design of a phase II trial of durvalumab treatment in patients with NSCLC ineligible for stage III chemoradiotherapy following radiation monotherapy (SPIRAL-RT study) ↗Therapeutic Advances in Medical Oncology · 2020 · PMID 32536981not yet assessed
-
Histone deacetylase inhibitor OBP‑801 and amrubicin synergistically inhibit the growth of squamous cell lung carcinoma by inducing mitochondrial ASK1‑dependent apoptosis ↗International Journal of Oncology · 2020 · PMID 32124968not yet assessed
-
<p>A Renal Impairment Subgroup Analysis of the Safety and Efficacy of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Chronic Non-Cancer Pain Receiving Opioid Therapy</p> ↗Journal of Pain Research · 2020 · PMID 32280263not yet assessed
-
Advanced <scp>G‐CSF</scp>‐producing non‐small cell lung cancer‐not otherwise specified, with favourable response to pembrolizumab monotherapy ↗Respirology Case Reports · 2020 · PMID 32695401not yet assessed
-
Respiratory complications of Stevens-Johnson syndrome (SJS): 3 cases of SJS-induced obstructive bronchiolitis ↗Allergology International · 2020 · PMID 32067932not yet assessed
-
The Quality of Life of Patients with Suspected Lung Cancer before and after Bronchoscopy and the Effect of Mirtazapine on the Depressive Status ↗Internal Medicine · 2020 · PMID 32612064not yet assessed
-
TTF-1 and c-MYC-defined Phenotypes of Large Cell Neuroendocrine Carcinoma and Delta-like Protein 3 Expression for Treatment Selection ↗Applied immunohistochemistry & molecular morphology · 2020 · PMID 33031101not yet assessed
-
Diverse Receptor Tyrosine Kinase Phosphorylation in Urine-Derived Tubular Epithelial Cells from Autosomal Dominant Polycystic Kidney Disease Patients ↗The Nephron journals/Nephron journals · 2020 · PMID 32799196not yet assessed
-
411P Impact of pre-treatment AXL expression on osimertinib efficacy in patients with non-small cell lung cancer with EGFR mutation ↗Annals of Oncology · 2020not yet assessed
-
not yet assessed
-
Randomized Phase II Study of First-Line Biweekly Gemcitabine and Carboplatin Versus Biweekly Gemcitabine and Carboplatin plus Maintenance Gemcitabine in Elderly Patients with Untreated Non-Small Cell Lung Cancer: LOGIK0801 ↗The Oncologist · 2020 · PMID 32385918not yet assessed
-
Abstract 4306: Retrospective analysis of docetaxel in combination with ramucirumab for previously treated non-small cell lung cancer patients ↗Cancer Research · 2020not yet assessed
-
Resistance to EGFR-TKI in lung cancer.月刊腫瘍内科 · 2020not yet assessed
-
ONO-7475, a novel AXL inhibitor, suppresses the adaptive resistance to initial EGFR-TKI treatment in EGFR-mutated NSCLC日本癌学会学術総会抄録集(Web) · 2020not yet assessed
-
放射線単独療法(SPIRAL-RT研究)後のステージIII化学放射線療法に不適格なNSCLC患者におけるデュルバルマブ治療の第II相試験の理論的根拠と設計【JST・京大機械翻訳】Therapeutic Advances in Medical Oncology · 2020not yet assessed
-
AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells ↗Nature Communications · 2019 · PMID 30651547not yet assessed
-
Tumor Neovascularization and Developments in Therapeutics ↗Cancers · 2019 · PMID 30845711not yet assessed
-
Retrospective efficacy analysis of immune checkpoint inhibitors in patients with EGFR‐mutated non‐small cell lung cancer ↗Cancer Medicine · 2019 · PMID 30790471not yet assessed
-
Epithelial-to-Mesenchymal Transition Is a Mechanism of ALK Inhibitor Resistance in Lung Cancer Independent of <i>ALK</i> Mutation Status ↗Cancer Research · 2019 · PMID 30737231not yet assessed
-
The role of the gut microbiome on the efficacy of immune checkpoint inhibitors in Japanese responder patients with advanced non-small cell lung cancer ↗Translational Lung Cancer Research · 2019 · PMID 32010563not yet assessed
-
Association of Sarcopenia with and Efficacy of Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer ↗Journal of Clinical Medicine · 2019 · PMID 30987236not yet assessed
-
Retrospective Efficacy Analysis of Immune Checkpoint Inhibitor Rechallenge in Patients with Non-Small Cell Lung Cancer ↗Journal of Clinical Medicine · 2019 · PMID 31906082not yet assessed
-
Safety and Usefulness of Cryobiopsy and Stamp Cytology for the Diagnosis of Peripheral Pulmonary Lesions ↗Cancers · 2019 · PMID 30909479not yet assessed
-
Carcinoembryonic antigen and CYFRA 21-1 responses as prognostic factors in advanced non-small cell lung cancer ↗Translational Lung Cancer Research · 2019 · PMID 31367536not yet assessed
-
Retrospective analysis of docetaxel in combination with ramucirumab for previously treated non-small cell lung cancer patients ↗Translational Lung Cancer Research · 2019 · PMID 31555518not yet assessed
-
The Effect of LKB1 Activity on the Sensitivity to PI3K/mTOR Inhibition in Non–Small Cell Lung Cancer ↗Journal of Thoracic Oncology · 2019 · PMID 30825612not yet assessed
-
Distribution and Activity of Lenvatinib in Brain Tumor Models of Human Anaplastic Thyroid Cancer Cells in Severe Combined Immune Deficient Mice ↗Molecular Cancer Therapeutics · 2019 · PMID 30926637not yet assessed
-
Osimertinib in Elderly Patients with Epidermal Growth Factor Receptor T790M-Positive Non-Small-Cell Lung Cancer Who Progressed During Prior Treatment: A Phase II Trial ↗The Oncologist · 2019 · PMID 30651400not yet assessed
-
Rationale and Design of a Phase II Trial of Osimertinib Combined With Bevacizumab in Patients With Untreated Epidermal Growth Factor Receptor-mutated Non–small-cell Lung Cancer and Malignant Pleural and/or Pericardial Effusion (SPIRAL II Study) ↗Clinical Lung Cancer · 2019 · PMID 30905617not yet assessed
-
Impact of bowel movement condition on immune checkpoint inhibitor efficacy in patients with advanced non‐small cell lung cancer ↗Thoracic Cancer · 2019 · PMID 30666802not yet assessed
-
Onset of action of naldemedine in the treatment of opioid-induced constipation in patients with chronic noncancer pain: results from 2 randomized, placebo-controlled, phase 3 trials ↗Pain · 2019 · PMID 31145214not yet assessed
-
Comparing three different anti-PD-L1 antibodies for immunohistochemical evaluation of small cell lung cancer ↗Lung Cancer · 2019 · PMID 31568887not yet assessed
-
Clinical Characteristics of Osimertinib Responder in Non-Small Cell Lung Cancer Patients with EGFR-T790M Mutation ↗Cancers · 2019 · PMID 30875919not yet assessed
-
Prognostic impact of pleural effusion in <i>EGFR</i>‐mutant non‐small cell lung cancer patients without brain metastasis ↗Thoracic Cancer · 2019 · PMID 30672656not yet assessed
-
The Influence of Renal or Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Naldemedine ↗Clinical Pharmacology in Drug Development · 2019 · PMID 30977959not yet assessed
-
Nicotine Induces Resistance to Erlotinib Therapy in Non-Small-Cell Lung Cancer Cells Treated with Serum from Human Patients ↗Cancers · 2019 · PMID 30818860not yet assessed
-
Phase II Study on Biweekly Combination Therapy of Gemcitabine plus Carboplatin for the Treatment of Elderly Patients with Advanced Non-Small Cell Lung Cancer ↗The Oncologist · 2019 · PMID 32162814not yet assessed
-
Phase II Study of S-1 and Paclitaxel Combination Therapy in Patients with Previously Treated Non-Small Cell Lung Cancer ↗The Oncologist · 2019 · PMID 31040252not yet assessed
-
The Impact of Immune-related Adverse Events on the Effect of Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer ↗Haigan · 2019not yet assessed
-
Rationale and design of a phase II study to evaluate prophylactic treatment of dacomitinib-induced dermatologic adverse events in epidermal growth factor receptor-mutated advanced non-small cell lung cancer (SPIRAL-Daco study) ↗Translational Lung Cancer Research · 2019 · PMID 31555524not yet assessed
-
Rationale and design of a phase II trial of osimertinib as first-line treatment for elderly patients with epidermal growth factor receptor mutation-positive advanced non-small cell lung cancer (SPIRAL-0 study) ↗Translational Lung Cancer Research · 2019 · PMID 32010586not yet assessed
-
Phase I/II Study of Docetaxel and S-1 in Previously-Treated Patients with Advanced Non-Small Cell Lung Cancer: LOGIK0408 ↗Journal of Clinical Medicine · 2019 · PMID 31842381not yet assessed
-
Abstract 4036: The efficacy of immune checkpoint inhibitors in patients with EGFR mutated non small cell lung cancer in retrospective analysis ↗Clinical Research (Excluding Clinical Trials) · 2019not yet assessed
-
Abstract 4899: The impact of the <i>EGFR</i>-T790M mutation detection by re-biopsy in EGFR mutant NSCLC patients in the retrospective analysis ↗Cancer Research · 2019not yet assessed
-
Abstract 3996: Search for prognosis prediction factors in treatment selection for elderly patients with EGFR negative advanced stage non-small cell lung cancer patients ↗Clinical Research (Excluding Clinical Trials) · 2019not yet assessed
-
Abstract 313: AXL confers intrinsic resistance to osimertinib and the emergence of tolerant cells ↗Experimental and Molecular Therapeutics · 2019not yet assessed
-
Phase II study to evaluate the peripheral blood mononuclear cell biomarker for nivolumab efficacy on previously treated non-small cell lung cancer subjects (NEJ029B: IMMUNITY-ONE) ↗Annals of Oncology · 2019not yet assessed
-
EP1.14-05 Clinical Characteristics of Osimertinib Responder in Non-Small Cell Lung Cancer Patients with EGFR-T790M Mutation ↗Journal of Thoracic Oncology · 2019not yet assessed
-
Abstract 4899: The impact of the<i>EGFR</i>-T790M mutation detection by re-biopsy in EGFR mutant NSCLC patients in the retrospective analysis ↗Clinical Research (Excluding Clinical Trials) · 2019not yet assessed
-
Abstract 3996: Search for prognosis prediction factors in treatment selection for elderly patients with EGFR negative advanced stage non-small cell lung cancer patients ↗Cancer Research · 2019not yet assessed
-
Abstract 4036: The efficacy of immune checkpoint inhibitors in patients with EGFR mutated non small cell lung cancer in retrospective analysis ↗Cancer Research · 2019not yet assessed
-
Abstract 313: AXL confers intrinsic resistance to osimertinib and the emergence of tolerant cells ↗Cancer Research · 2019not yet assessed
-
Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC ↗Nature Communications · 2018 · PMID 30097569not yet assessed
-
Long-term use of naldemedine in the treatment of opioid-induced constipation in patients with chronic noncancer pain: a randomized, double-blind, placebo-controlled phase 3 study ↗Pain · 2018 · PMID 29419653not yet assessed
-
Advanced Non-Small-Cell Lung Cancer in Elderly Patients: Patient Features and Therapeutic Management ↗BioMed Research International · 2018 · PMID 29854794not yet assessed
-
Foretinib Overcomes Entrectinib Resistance Associated with the <i>NTRK1</i> G667C Mutation in <i>NTRK1</i> Fusion–Positive Tumor Cells in a Brain Metastasis Model ↗Clinical Cancer Research · 2018 · PMID 29463555not yet assessed
-
Pulmonary carcinosarcoma showing an obvious response to pazopanib: a case report ↗BMC Pulmonary Medicine · 2018 · PMID 30541518not yet assessed
-
Treatment rationale and design of the SPIRAL study ↗Medicine · 2018 · PMID 29879078not yet assessed
-
Treatment rationale and design of the RAMNITA study ↗Medicine · 2018 · PMID 29879079not yet assessed
-
Successful sequential treatment of refractory tumors caused by small cell carcinoma transformation and EGFR-T790M mutation diagnosed by repeated genetic testing in a patient with lung adenocarcinoma harboring epidermal growth factor receptor mutations: A case report ↗Respiratory Medicine Case Reports · 2018 · PMID 30310765not yet assessed
-
Phase I study of S-1 plus paclitaxel combination therapy as a first-line treatment in elderly patients with advanced non-small cell lung cancer ↗Investigational New Drugs · 2018 · PMID 30121935not yet assessed
-
Nab-paclitaxel maintenance therapy following carboplatin + nab-paclitaxel combination therapy in chemotherapy naïve patients with advanced non-small cell lung cancer: multicenter, open-label, single-arm phase II trial ↗Investigational New Drugs · 2018 · PMID 29846848not yet assessed
-
Effective combined therapy with ramucirumab for advanced pulmonary pleomorphic carcinoma ↗Respirology Case Reports · 2018 · PMID 30275953not yet assessed
-
The impact of the tumor shrinkage by initial EGFR inhibitors according to the detection of EGFR-T790M mutation in patients with non-small cell lung cancer harboring EGFR mutations ↗BMC Cancer · 2018 · PMID 30537950not yet assessed
-
A Phase II Study of S-1 and Paclitaxel Combination Therapy as a First-Line Treatment in Elderly Patients with Advanced Non-Small Cell Lung Cancer ↗The Oncologist · 2018 · PMID 30578309not yet assessed
-
An observational study of the epidermal growth factor receptor-tyrosine kinase inhibitor resistance mechanism in epidermal growth factor receptor gene mutation-positive non-small cell lung cancer ↗Medicine · 2018 · PMID 30290647not yet assessed
-
Naldemedine Is Effective in the Treatment of Opioid-Induced Constipation in Chronic Non-Cancer Pain in Subjects With or Without Inadequate Response to Laxatives ↗The American Journal of Gastroenterology · 2018not yet assessed
-
not yet assessed
-
Mo1571 - Safety of Naldemedine for the Treatment of Opioid-Induced Constipation in Subjects with Chronic Non-Cancer Pain Receiving Opioid Therapy: Results of Three Global Phase 3 Clinical Trials ↗Gastroenterology · 2018not yet assessed
-
Abstract 1692: The impact of neutrophil/lymphocyte ratio as the predictive marker to anti-PD-1 antibody treatment in NSCLC patients ↗Cancer Research · 2018not yet assessed
-
Abstract 5843: The efficacy of a histone deacetylase inhibitor in combination with a MEK inhibitor in lung cancer cells harboring RAS mutations ↗Cancer Research · 2018not yet assessed
-
Abstract 2839: Notch3-dependent beta-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC ↗Cancer Research · 2018not yet assessed
-
P3.01-80 Retrospective Analysis of the Impact of EGFR T790M Mutation Detection by Re-Biopsy in Patients with NSCLC Harboring EGFR Mutations. ↗Journal of Thoracic Oncology · 2018not yet assessed
-
P1.01-102 Retrospective Analysis of Immune Checkpoint Inhibitors in Patients with EGFR Mutated Non-Small Cell Lung Cancer in a Japanese Cohort ↗Journal of Thoracic Oncology · 2018not yet assessed
-
Naldemedine versus placebo for opioid-induced constipation (COMPOSE-1 and COMPOSE-2): two multicentre, phase 3, double-blind, randomised, parallel-group trials ↗The Lancet. Gastroenterology & hepatology · 2017 · PMID 28576452not yet assessed
-
<i>MET</i> Copy Number Gain Is Associated with Gefitinib Resistance in Leptomeningeal Carcinomatosis of <i>EGFR</i> -mutant Lung Cancer ↗Molecular Cancer Therapeutics · 2017 · PMID 28138027not yet assessed
-
Histone Deacetylase Inhibition Enhances the Antitumor Activity of a MEK Inhibitor in Lung Cancer Cells Harboring <i>RAS</i> Mutations ↗Molecular Cancer Therapeutics · 2017 · PMID 29079711not yet assessed
-
Impact of <scp>MET</scp> inhibition on small‐cell lung cancer cells showing aberrant activation of the hepatocyte growth factor/ <scp>MET</scp> pathway ↗Cancer Science · 2017 · PMID 28474864not yet assessed
-
Podoplanin promotes progression of malignant pleural mesothelioma by regulating motility and focus formation ↗Cancer Science · 2017 · PMID 28182302not yet assessed
-
A case of aseptic meningitis without neck rigidity occurring in a metastatic melanoma patient treated with ipilimumab ↗European Journal of Dermatology · 2017 · PMID 28007669not yet assessed
-
Notch3-Dependent β-Catenin Signaling Mediates EGFR TKI Drug Persistence in EGFR Mutant NSCLC ↗Journal of Thoracic Oncology · 2017not yet assessed
-
<i>In vivo</i> imaging xenograft models for the evaluation of anti‐brain tumor efficacy of targeted drugs ↗Cancer Medicine · 2017 · PMID 29125233not yet assessed
-
Androgen replacement therapy for cancer-related symptoms in male advanced cancer patients: study protocol for a randomised prospective trial (ARTFORM study) ↗The Journal of Medical Investigation · 2017 · PMID 28954982not yet assessed
-
Two cases of primary malignant melanoma of the esophagus ↗Skin Cancer · 2017not yet assessed
-
P3.03-002 Histone Deacetylase Inhibition Enhances the Antitumor Activity of a MEK Inhibitor in Lung Cancer Cells Harboring RAS Mutations ↗Journal of Thoracic Oncology · 2017not yet assessed
-
MA07.10 HDAC Inhibition Overcomes Crizotinib-Resistance by Mesenchymal-Epithelial Transition (MET) in EML4-ALK Lung Cancer Cells ↗Journal of Thoracic Oncology · 2017not yet assessed
-
OA08.03 MET Copy Number Gain Associates with Gefitinib Resistance in Leptomeningeal Carcinomatosis of EGFR Mutant Lung Cancer ↗Journal of Thoracic Oncology · 2017not yet assessed
-
Abstract 5535: Effect of LKB1 activity on the sensitivity to PI3K/mTOR inhibitor in non-small-cell lung cancer ↗Cancer Research · 2017not yet assessed
-
P1.03-032 In vivo Imaging Models for Preclinical Screening of Molecular Targeted Drugs against Brain Metastasis ↗Journal of Thoracic Oncology · 2017not yet assessed
-
P2.03b-069 LKB1 Loss is a Novel Determinant of MEK Sensitivity Due to Alterations in AKT/FOXO3 Signaling ↗Journal of Thoracic Oncology · 2017not yet assessed
-
Effect of Naldemedine on Frequency of Spontaneous Bowel Movements and Associated Symptoms ↗The American Journal of Gastroenterology · 2017not yet assessed
-
Histone Deacetylase 3 Inhibition Overcomes <i>BIM</i> Deletion Polymorphism–Mediated Osimertinib Resistance in <i>EGFR-</i> Mutant Lung Cancer ↗Clinical Cancer Research · 2016 · PMID 27986747not yet assessed
-
A Phase 2b, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Chronic Noncancer Pain ↗Pain Medicine · 2016 · PMID 28371937not yet assessed
-
Amphiregulin triggered epidermal growth factor receptor activation confers <i>in vivo</i> crizotinib‐resistance of <scp>EML</scp>4‐<scp>ALK</scp> lung cancer and circumvention by epidermal growth factor receptor inhibitors ↗Cancer Science · 2016 · PMID 27783866not yet assessed
-
A Transcriptional Signature Identifies LKB1 Functional Status as a Novel Determinant of MEK Sensitivity in Lung Adenocarcinoma ↗Cancer Research · 2016 · PMID 27821489not yet assessed
-
598 Efficacy and Safety of Naldemedine for the Treatment of Opioid-Induced Constipation in Subjects With Chronic Non-Cancer Pain Receiving Opioid Therapy: Results From Two Phase 3 Clinical Trials ↗Gastroenterology · 2016not yet assessed
-
(426) Effect of naldemedine, a peripherally acting μ-opioid receptor antagonist, on QT interval ↗Journal of Pain · 2016not yet assessed
-
not yet assessed
-
Onset of Action of Naldemedine in the Treatment of Opioid-Induced Constipation in Patients with Chronic Non-Cancer Pain: Results from Two Randomized, Placebo-Controlled Phase 3 Trials ↗The American Journal of Gastroenterology · 2016not yet assessed
-
EUSにおける主膵管拡張を契機とし,連続膵液細胞診(serial pancreatic juice aspiration cytological examination:SPACE)にて診断された膵上皮内癌の1切除例Endoscopic forum for digestive disease · 2016not yet assessed
-
Abstract 4763: Targeted therapy by MET inhibitors against small-cell lung cancer with aberrant activation of HGF/MET pathway ↗Cancer Research · 2016not yet assessed
-
Abstract 4661: Loss of LKB1 in NSCLC confers sensitivity to MEK inhibition by regulating activation of AKT-FOXO3 pathway ↗Cancer Research · 2016not yet assessed
-
High efficacy of third generation EGFR inhibitor AZD9291 in a leptomeningeal carcinomatosis model with <i>EGFR</i>-mutant lung cancer cells ↗Oncotarget · 2015 · PMID 26716903not yet assessed
-
Efficacy and safety of 40 mg or 60 mg duloxetine in <scp>J</scp>apanese adults with diabetic neuropathic pain: Results from a randomized, 52‐week, open‐label study ↗Journal of Diabetes Investigation · 2015 · PMID 26816607not yet assessed
-
Akt Kinase-Interacting Protein 1 Signals through CREB to Drive Diffuse Malignant Mesothelioma ↗Cancer Research · 2015 · PMID 26294214not yet assessed
-
Organ‐specific efficacy of <scp>HSP</scp>90 inhibitor in multiple‐organ metastasis model of chemorefractory small cell lung cancer ↗International Journal of Cancer · 2015 · PMID 26379118not yet assessed
-
901e A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Naldemedine for the Treatment of Opioid-Induced Constipation in Patients With Chronic Non-Cancer Pain ↗Gastroenterology · 2015not yet assessed
-
Therapeutic activity of glycoengineered anti‐GM2 antibodies to malignant mesothelioma. GM2 expression in a clinical malignant pleural mesothelioma specimen determined by anti‐GM2 antibody BIW‐8962 ↗Cancer Science · 2015not yet assessed
-
Abstract 3555: Akt kinase-interacting protein1 as a potential therapeutics target in CREB1 signaling in malignant pleural mesothelioma ↗Cancer Research · 2015not yet assessed
-
Toxicity profiles of crizotinib plus afatinib or WZ4002 <i>in</i><i>vivo</i>. ↗Figshare · 2015not yet assessed
-
Therapeutic activity of glycoengineered anti-GM2 antibodies against malignant pleural mesotheliomaInstitutional Repositories DataBase (IRDB) · 2015not yet assessed
-
Receptor ligand-triggered resistance to alectinib and its circumvention by Hsp90 inhibition in EML4-ALK lung cancer cells ↗Oncotarget · 2014 · PMID 24952482not yet assessed
-
Triple Inhibition of EGFR, Met, and VEGF Suppresses Regrowth of HGF-Triggered, Erlotinib-Resistant Lung Cancer Harboring an EGFR Mutation ↗Journal of Thoracic Oncology · 2014 · PMID 24828661not yet assessed
-
Therapeutic activity of glycoengineered anti‐<scp>GM</scp>2 antibodies against malignant pleural mesothelioma ↗Cancer Science · 2014 · PMID 25421609not yet assessed
-
Expression of Akt Kinase-Interacting Protein 1, a Scaffold Protein of the PI3K/PDK1/Akt Pathway, in Pancreatic Cancer ↗Pancreas · 2014 · PMID 25036909not yet assessed
-
Predictive Significance of Actinin-4 (ACTN4) Gene Expression in Early-Stage Non-Small Cell Lung Cancer (NSCLC) ↗International Journal of Radiation Oncology*Biology*Physics · 2014not yet assessed
-
Abstract 2762: Akt kinase-interacting protein1, a novel therapeutic target for lung cancer with EGFR-activating and gatekeeper mutations ↗Cancer Research · 2014not yet assessed
-
Expression of Akt kinase-interacting protein 1 (Aki1), a scaffold protein of the PI3K/PDK1/Akt pathway, in pancreatic cancer. ↗Pancreatology · 2014not yet assessed
-
EGFR-TKI Resistance Due to <i>BIM</i> Polymorphism Can Be Circumvented in Combination with HDAC Inhibition ↗Cancer Research · 2013 · PMID 23382048not yet assessed
-
Ability of the Met Kinase Inhibitor Crizotinib and New Generation EGFR Inhibitors to Overcome Resistance to EGFR Inhibitors ↗PLoS ONE · 2013 · PMID 24386407not yet assessed
-
mTOR Inhibitors Control the Growth of EGFR Mutant Lung Cancer Even after Acquiring Resistance by HGF ↗PLoS ONE · 2013 · PMID 23690929not yet assessed
-
The novel phosphoinositide 3‐kinase–mammalian target of rapamycin inhibitor, BEZ235, circumvents erlotinib resistance of <i>epidermal growth factor receptor</i> mutant lung cancer cells triggered by hepatocyte growth factor ↗International Journal of Cancer · 2013 · PMID 23319394not yet assessed
-
Paracrine activation of MET promotes peritoneal carcinomatosis in scirrhous gastric cancer ↗Cancer Science · 2013 · PMID 24118504not yet assessed
-
Antitumor effect and antiangiogenic potential of the mTOR inhibitor temsirolimus against malignant pleural mesothelioma ↗Oncology Reports · 2013 · PMID 24378576not yet assessed
-
[Efficacy of low-dose erlotinib against gefitinib-induced hepatotoxicity in a patient with lung adenocarcinoma harboring EGFR mutations]. ↗PubMed · 2013 · PMID 23306923not yet assessed
-
Synchronous Triple Cancers of the Pancreas, Stomach, and Cecum Treated with S-1 Followed by Pancrelipase Treatment of Pancreatic Exocrine Insufficiency ↗PubMed · 2013 · PMID 24018598not yet assessed
-
Paracrine activation of MET promotes peritoneal carcinomatosis in scirrhous gastric cancer ↗Institutional Repositories DataBase (IRDB) · 2013not yet assessed
-
Paracrine Receptor Activation by Microenvironment Triggers Bypass Survival Signals and ALK Inhibitor Resistance in EML4-ALK Lung Cancer Cells ↗Clinical Cancer Research · 2012 · PMID 22553343not yet assessed
-
Combined Therapy with Mutant-Selective EGFR Inhibitor and Met Kinase Inhibitor for Overcoming Erlotinib Resistance in <i>EGFR</i> -Mutant Lung Cancer ↗Molecular Cancer Therapeutics · 2012 · PMID 22844075not yet assessed
-
Met Kinase Inhibitor E7050 Reverses Three Different Mechanisms of Hepatocyte Growth Factor–Induced Tyrosine Kinase Inhibitor Resistance in <i>EGFR</i> Mutant Lung Cancer ↗Clinical Cancer Research · 2012 · PMID 22317763not yet assessed
-
Ligand‐triggered resistance to molecular targeted drugs in lung cancer: Roles of hepatocyte growth factor and epidermal growth factor receptor ligands ↗Cancer Science · 2012 · PMID 22435662not yet assessed
-
Dual Inhibition of Met Kinase and Angiogenesis to Overcome HGF-Induced EGFR-TKI Resistance in EGFR Mutant Lung Cancer ↗American Journal Of Pathology · 2012 · PMID 22789825not yet assessed
-
Hsp90 Inhibition Overcomes HGF-Triggering Resistance to EGFR-TKIs in EGFR-Mutant Lung Cancer by Decreasing Client Protein Expression and Angiogenesis ↗Journal of Thoracic Oncology · 2012 · PMID 22592212not yet assessed
-
Akt kinase-interacting protein1, a novel therapeutic target for lung cancer with EGFR-activating and gatekeeper mutations ↗Oncogene · 2012 · PMID 23045273not yet assessed
-
Prognostic value of acquired resistance-related molecules in Japanese patients with NSCLC treated with an EGFR-TKI. ↗PubMed · 2012 · PMID 22993320not yet assessed
-
[Cancer of unknown primary site with epidermal growth factor receptor mutation for which gefitinib proved effective]. ↗PubMed · 2012 · PMID 22902462not yet assessed
-
Met Kinase Inhibitor E7050 Reverses Three Different Mechanisms of Hepatocyte Growth Factor-Induced Tyrosine Kinase Inhibitor Resistance in EGFR Mutant Lung Cancer ↗Annals of Oncology · 2012not yet assessed
-
[A case of poorly-differentiated neuroendocrine carcinoma of the ascending colon with multiple liver metastases successfully treated with cisplatin and irinotecan]. ↗PubMed · 2012 · PMID 22996784not yet assessed
-
Abstract PR7: Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor-resistance in EML4-ALK lung cancer cells ↗Clinical Cancer Research · 2012not yet assessed
-
Abstract B21: E7050, a Met kinase inhibitor, reverses three different mechanisms of hepatocyte growth factor-induced resistance to tyrosine kinase inhibitors in EGFR mutant lung cancer cells ↗Clinical Cancer Research · 2012not yet assessed
-
Abstract 1896: Hepatocyte growth factor induces resistance to anti-epidermal growth factor receptor antibody in lung cancer ↗Cancer Research · 2012not yet assessed
-
not yet assessed
-
The Resistance to EGFR-TKIS in Lung Cancer ↗Annals of Oncology · 2012not yet assessed
-
Hepatocyte Growth Factor Expression in EGFR Mutant Lung Cancer with Intrinsic and Acquired Resistance to Tyrosine Kinase Inhibitors in a Japanese Cohort ↗Journal of Thoracic Oncology · 2011 · PMID 22052230not yet assessed
-
Transient PI3K Inhibition Induces Apoptosis and Overcomes HGF-Mediated Resistance to EGFR-TKIs in <i>EGFR</i> Mutant Lung Cancer ↗Clinical Cancer Research · 2011 · PMID 21220474not yet assessed
-
Pleural Mesothelioma Instigates Tumor-Associated Fibroblasts To Promote Progression via a Malignant Cytokine Network ↗American Journal Of Pathology · 2011 · PMID 21763682not yet assessed
-
The EGFR Ligands Amphiregulin and Heparin-Binding EGF-like Growth Factor Promote Peritoneal Carcinomatosis in CXCR4-Expressing Gastric Cancer ↗Clinical Cancer Research · 2011 · PMID 21482691not yet assessed
-
Hepatocyte Growth Factor Induces Resistance to Anti-Epidermal Growth Factor Receptor Antibody in Lung Cancer ↗Journal of Thoracic Oncology · 2011 · PMID 22089117not yet assessed
-
Genetically engineered humanized anti‐ganglioside GM2 antibody against multiple organ metastasis produced by GM2‐expressing small‐cell lung cancer cells ↗Cancer Science · 2011 · PMID 21895875not yet assessed
-
E7080 Suppresses Hematogenous Multiple Organ Metastases of Lung Cancer Cells with Nonmutated Epidermal Growth Factor Receptor ↗Molecular Cancer Therapeutics · 2011 · PMID 21551260not yet assessed
-
HGF-MET in Resistance to EGFR Tyrosine Kinase Inhibitors in Lung Cancer ↗Current Signal Transduction Therapy · 2011not yet assessed
-
Hepatocyte growth factor expression in <i>EGFR</i>-mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort. ↗Journal of Clinical Oncology · 2011not yet assessed
-
Abstract 1730: Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in <i>EGFR</i> mutant lung cancer ↗Cancer Research · 2011not yet assessed
-
Cancer Mutant Lung EGFR HGF-Mediated Resistance to EGFR-TKIs in Transient PI3K Inhibition Induces Apoptosis and Overcomes2011not yet assessed
-
[PI3K inhibitor]. ↗PubMed · 2011 · PMID 21368457not yet assessed
-
Metastatic renal cell carcinoma complicated with diffuse alveolar hemorrhage: a rare adverse effect of sunitinib ↗International Journal of Clinical Oncology · 2010 · PMID 20602135not yet assessed
-
The Role of Percutaneous Needle Biopsy in Differentiation of Renal Tumors ↗Japanese Journal of Clinical Oncology · 2010 · PMID 20601495not yet assessed
-
not yet assessed
-
[Combined chemotherapy with cisplatin plus vinorelbine showed efficacy in a case of metastatic primary cutaneous adenoid cystic carcinoma]. ↗PubMed · 2010 · PMID 20716883not yet assessed
-
Abstract 629: Hepatocyte growth factor induces resistance to an irreversible epidermal growth factor receptor inhibitor in <i>EGFR</i>-T790M mutant lung cancer ↗Cancer Research · 2010not yet assessed
-
not yet assessed
-
Abstract 626: Therapeutic effect of HGF inhibitors against HGF-induced EGFR-TKI resistance in lung cancer harboring <i>EGFR</i> mutations ↗Cancer Research · 2010not yet assessed
-
Crosstalk to Stromal Fibroblasts Induces Resistance of Lung Cancer to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors ↗Clinical Cancer Research · 2009 · PMID 19843665not yet assessed
-
Hepatocyte Growth Factor Reduces Susceptibility to an Irreversible Epidermal Growth Factor Receptor Inhibitor in <i>EGFR</i> -T790M Mutant Lung Cancer ↗Clinical Cancer Research · 2009 · PMID 20008840not yet assessed
-
E7080, a Multi–Tyrosine Kinase Inhibitor, Suppresses the Progression of Malignant Pleural Mesothelioma with Different Proangiogenic Cytokine Production Profiles ↗Clinical Cancer Research · 2009 · PMID 19934291not yet assessed
-
A Bone Metastasis Model With Osteolytic and Osteoblastic Properties of Human Lung Cancer ACC-LC-319/bone2 in Natural Killer Cell-Depleted Severe Combined Immunodeficient Mice ↗Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · 2009 · PMID 19806789not yet assessed
-
Novel dual targeting strategy with vandetanib induces tumor cell apoptosis and inhibits angiogenesis in malignant pleural mesothelioma cells expressing RET oncogenic rearrangementKanazawa University Repository for Academic Resources (DSpace) (Kanazawa University) · 2009not yet assessed
-
Intensification therapy with anti-parathyroid hormone-related protein antibody plus zoledronic acid for bone metastases of small cell lung cancer cells in severe combined immunodeficient mice ↗Molecular Cancer Therapeutics · 2009 · PMID 19139120not yet assessed
-
Combined chemotherapy with carboplatin plus irinotecan showed favorable efficacy in a patient with relapsed small cell carcinoma of the prostate complicated with meningeal carcinomatosis ↗International Journal of Clinical Oncology · 2009 · PMID 19856060not yet assessed
-
Autosomal dominant limb-girdle muscular dystrophy with ankle joint contracture ↗Acta Neurologica Scandinavica · 2009 · PMID 10478586not yet assessed
-
Cancer of Unknown Primary Site in which Tumor Marker-Oriented Chemotherapy was Effective and Pancreatic Cancer was Finally Confirmed at Autopsy ↗Internal Medicine · 2009 · PMID 19755768not yet assessed
-
Lysophospahatidic acid stimulates the proliferation and motility of malignant pleural mesothelioma cells through lysophosphatidic acid receptors, LPA1 and LPA2Institutional Repositories DataBase (IRDB) · 2009not yet assessed
-
Hepatocyte growth factor as inducer of gefitinib resistance in non-small cell lung cancer harboring <i>EGFR</i> activating mutations ↗Journal of Clinical Oncology · 2009not yet assessed
-
Abstract A178: Role of tumor and host-derived HGF in drug resistance to EGFR inhibitors in EGFR activating mutation-positive lung cancer ↗Molecular Cancer Therapeutics · 2009not yet assessed
-
501 INHIBITION OF CELL PROLIFERATION BY ALPHA-ACTININ-4-MEDIATED ENDOCYTOSIS AND MASS SPECTROMETRY ANALYSIS OF THE NATIVE PROTEIN COMPLEX CONTAINING ACTININ-4 IN PROSTATE CANCER CELLS ↗European Urology Supplements · 2009not yet assessed
-
Flat adenoma–carcinoma sequence with high‐malignancy potential as demonstrated by CD10 and β‐catenin expression: a different pathway from the polypoid adenoma–carcinoma sequence ↗Histopathology · 2008 · PMID 18370954not yet assessed
-
Lysophosphatidic acid stimulates the proliferation and motility of malignant pleural mesothelioma cells through lysophosphatidic acid receptors, LPA<sub>1</sub> and LPA<sub>2</sub> ↗Cancer Science · 2008 · PMID 18754873not yet assessed
-
Novel dual targeting strategy with vandetanib induces tumor cell apoptosis and inhibits angiogenesis in malignant pleural mesothelioma cells expressing RET oncogenic rearrangement ↗Cancer Letters · 2008 · PMID 18364248not yet assessed
-
Lysophosphatidic acid stimulates the proliferation and motility of malignant pleural mesothelioma cells through lysophosphatidic acid receptors, LPA1 and LPA2Institutional Repositories DataBase (IRDB) · 2008not yet assessed
-
Overexpression of inducible nitric oxide synthase and accumulation of 8‐OHdG in nasopharyngeal carcinoma ↗Histopathology · 2007 · PMID 18184270not yet assessed
-
TSU-68, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, suppressed the production of experimental brain metastasis by 3LL cells.Molecular Cancer Therapeutics · 2007not yet assessed
-
Overexpression of manganese superoxide dismutase by N-acetylcysteine in hyperoxic lung injury ↗Respiratory Medicine · 2006 · PMID 17010595not yet assessed
-
Thioredoxin-1 protects against hyperoxia-induced apoptosis in cells of the alveolar walls ↗Pulmonary Pharmacology & Therapeutics · 2006 · PMID 17045827not yet assessed
-
Phase I/II trial of biweekly docetaxel and cisplatin with concurrent thoracic radiation for stage III non-small-cell lung cancer ↗Cancer Chemotherapy and Pharmacology · 2006 · PMID 16565832not yet assessed
-
A novel potent inhibitor of inducible nitric oxide synthase, ONO-1714, reduces hyperoxic lung injury in mice ↗Respiratory Medicine · 2006 · PMID 16982182not yet assessed
-
Signal Pathway of Eotaxin Production by Human Nasal Fibroblast ↗Journal of Allergy and Clinical Immunology · 2006not yet assessed
-
[A case of sarcoidosis with diffuse pulmonary arteriovenous malformations]. ↗PubMed · 2005 · PMID 15969215not yet assessed
-
[Spinal cord metastases in lung cancer: a clinical review of four cases]. ↗PubMed · 2005 · PMID 15969211not yet assessed
-
[A case of non-mucin-producing papillary adenocarcinoma with a 19-year clinical history before operation]. ↗PubMed · 2005 · PMID 15969214not yet assessed
-
Tandospirone in the Treatment of Generalised Anxiety Disorder and Mixed Anxiety-Depression ↗Clinical Drug Investigation · 2004 · PMID 17516698not yet assessed
-
[A case of solitary endobronchial metastasis of prostatic cancer]. ↗PubMed · 2004 · PMID 15651277not yet assessed
-
[Severe asthma complicated with large mucoid impaction: successful removal with balloon catheter]. ↗PubMed · 2004 · PMID 15566007not yet assessed
-
The irreality of beauty and stylizationMedical Entomology and Zoology · 1999not yet assessed
-
[Molecular physiopathology of Alzheimer's disease]. ↗PubMed · 1998 · PMID 9549175not yet assessed
-
A case of acute monoblastic leukemia with breast tumorRinshō hōshasen · 1992not yet assessed
-
,,Die Logik der Philosophie"Nochmals Uberlegt : Lask und HegelArts and Social Sciences Journal · 1991not yet assessed
-
[Clinical application of Xe-133 SPECT]. ↗PubMed · 1991 · PMID 1886239not yet assessed
-
[Prognosis of patients with primary pulmonary hypertension]. ↗PubMed · 1989 · PMID 2641781not yet assessed
-
Studies on antigen of human colon cancer. ↗Nihon Daicho Komonbyo Gakkai Zasshi · 1986not yet assessed
-
(untitled) ↗QUARTERLY JOURNAL OF THE JAPAN WELDING SOCIETY · 1984not yet assessed
-
(untitled) ↗QUARTERLY JOURNAL OF THE JAPAN WELDING SOCIETY · 1983not yet assessed
-
(untitled) ↗QUARTERLY JOURNAL OF THE JAPAN WELDING SOCIETY · 1983not yet assessed
-
Extraction and preliminary characterization of tumor antigens in human bronchogenic adenocarcinoma and squamous cell carcinoma ↗European Journal of Cancer (1965) · 1980 · PMID 6773777not yet assessed
-
Cyclic alteration of electrophoretic property associated with growth circle in HeLa S3 cells. ↗PubMed · 1977 · PMID 267515not yet assessed
-
[Hemodynamic study of respiratory insufficiency after open heart surgery]. ↗PubMed · 1975 · PMID 1170238not yet assessed
-
33. Studies on hemingron metabolish during muscular exercise体力科學 · 1959not yet assessed
-
Androgen replacement therapy for cancer-related symptoms in male advanced cancer patients: Study protocol for a randomised prospective trial (ARTFORM study) ↗Institutional Repositories DataBase (IRDB) ·not yet assessed
Full bibliography from OpenAlex; reproducibility verdicts matched by PMID.
Author attribution follows OpenAlex disambiguation, which is imperfect — a researcher's papers can be split across profiles or mixed with a namesake.
Merged across profiles sharing this ORCID where present. See every “Yamada T” paper on PubMed ↗